GLP-1 Receptor Agonists in Athletic Populations: Lean Mass Attrition, Glycogen Metabolism, Inflammatory Recovery, and WADA Status

GLP-1RA-mediated weight loss in sedentary trial populations produces lean mass loss representing 25-40% of total mass lost. This is disproportionate to what is seen with equivalent isocaloric restriction combined with structured exercise, indicating that GLP-1-specific mechanisms beyond simple caloric deficit are contributing to lean mass catabolism. The proposed mechanisms include: GLP-1-mediated appetite suppression driving dietary protein intake below muscle protein synthesis maintenance thresholds, GLP-1R expression in skeletal muscle that may have direct effects on muscle protein turnover, and accelerated weight loss rate (faster than the body can preferentially mobilize adipose) promoting lean mass catabolism.

In studies incorporating structured resistance training (≥3 sessions per week), lean mass loss falls to approximately 10-15% of total weight lost — a substantially improved ratio, though still quantitatively real. The training-mediated mitigation operates through mechanical loading of muscle fibers stimulating mTORC1-dependent muscle protein synthesis, which creates an anabolic signal countervailing the GLP-1-associated catabolic environment. Leucine availability (from protein intake) is the rate-limiting co-stimulus for mTORC1 activation — establishing why protein targets (1.6-2.2g/kg/day) and resistance training are mechanistically interdependent rather than independently additive.

The lean mass loss worsens with age due to the declining anabolic sensitivity of aging muscle to both mechanical loading and leucine stimulus (anabolic resistance). Masters athletes (age >45) on GLP-1 therapy have attenuated mTORC1 responses per unit of training volume and protein intake, requiring higher protein targets and training frequency to achieve equivalent lean mass preservation compared to younger athletes.

GLP-1RAs improve peripheral insulin sensitivity through multiple mechanisms: GLP-1R-mediated enhancement of glucose-dependent insulin secretion, reduced hepatic glucose output, and GLP-1R expression in skeletal muscle facilitating direct glucose uptake independent of insulin. The net clinical effect is substantially improved insulin sensitivity, which directly influences post-exercise glycogen repletion dynamics.

Post-exercise glycogen repletion is rate-limited by skeletal muscle glucose uptake, which is insulin-dependent (via GLUT4 translocation) and partially insulin-independent (exercise-stimulated GLUT4 translocation). The insulin-dependent component is enhanced when insulin sensitivity is high: less insulin is required to achieve equivalent GLUT4 stimulation, and the peripheral glucose clearance rate at any given insulin concentration is higher. This translates to more efficient muscle glycogen repletion in the hours following training — a direct benefit for athletes with high training frequency who need to maximize the inter-session recovery window.

The practical implication for high-frequency training athletes: the post-exercise carbohydrate window (0-90 minutes post-exercise) becomes more efficient on GLP-1 therapy as insulin sensitivity improves. The same carbohydrate intake drives more glycogen storage. Conversely, the GLP-1-mediated appetite suppression can make consuming adequate post-exercise carbohydrates difficult — a tension that requires intentional nutritional timing regardless of hunger signals.

Systemic inflammation impairs athletic recovery through multiple mechanisms: elevated TNF-α and IL-6 suppress muscle protein synthesis signaling (competing with anabolic IGF-1 and mTORC1 pathways), elevated CRP correlates with delayed DOMS resolution and impaired satellite cell activation for muscle repair, and chronic low-grade inflammation accelerates muscle protein degradation via ubiquitin-proteasome pathway upregulation. In overweight or metabolically compromised athletes, adipose-derived chronic inflammation creates a basal pro-inflammatory state that degrades the signal-to-noise ratio for acute exercise-induced inflammatory responses necessary for adaptation.

GLP-1 receptor agonists produce significant and consistent reductions in CRP and IL-6 at 12-24 weeks of treatment — effect sizes in the published literature range from 20-40% reduction in CRP from baseline. The mechanism involves both weight-mediated (reduced adipose inflammatory cytokine secretion) and weight-independent (direct GLP-1R-mediated effects on macrophage polarization toward anti-inflammatory M2 phenotype) pathways. Reduced systemic IL-6 improves muscle protein synthesis efficiency by reducing the competing suppression of anabolic signaling, and the improved macrophage polarization may enhance satellite cell-mediated muscle repair following eccentric damage.

The SELECT trial (2023, n=17,604, semaglutide in subjects with overweight/obesity and established cardiovascular disease) documented a 20% reduction in major cardiovascular events over a mean follow-up of 34 months. For masters athletes with metabolic risk factors, this cardiovascular risk reduction represents a clinically significant benefit independent of performance considerations — particularly relevant given the elevated cardiac event risk in masters endurance athletes performing high-volume training.

Creatine monohydrate at 5g/day represents the highest-evidence, most specific intervention for lean mass attrition mitigation during GLP-1RA-mediated weight loss. Creatine's mechanism in this context operates through two pathways: (1) enhanced phosphocreatine availability in muscle, supporting higher training volume capacity and therefore greater mTORC1 mechanical stimulus for muscle protein synthesis, and (2) direct anti-catabolic effects via creatine kinase/phosphocreatine influence on cellular energy status signaling, reducing ubiquitin-proteasome pathway activation. Studies specifically examining lean mass outcomes during weight loss interventions with and without creatine supplementation consistently show attenuated lean mass loss with creatine — the data on GLP-1 specifically is limited but consistent with the broader weight-loss context.

Protein intake thresholds for athletes on GLP-1 therapy require upward adjustment from general population GLP-1 clinical context. The 1.6-2.2g/kg/day range represents the minimum for active muscle protein synthesis support during weight loss in athletes; masters athletes may benefit from the upper end of this range given anabolic resistance. GLP-1-mediated appetite suppression creates a compliance challenge — monitoring protein intake via dietary tracking for the first 8-12 weeks is appropriate to ensure targets are being met despite suppressed appetite signals.

On WADA regulatory status: semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) are not included on the 2025 WADA Prohibited List in any category — they are permitted both in-competition and out-of-competition. This is distinct from peptide GH secretagogues including ipamorelin, CJC-1295, and GHRP-6, which are prohibited under WADA Section 2 (Peptide Hormones, Growth Factors, Related Substances and Mimetics). Athletes combining GLP-1RA therapy with peptide-based recovery protocols must verify the WADA status of each compound independently — the GLP-1RA permissibility does not extend to co-administered peptides.